Pedmark Shows Promising Results in Japan Study — Reduced Hearing Loss with Equivalent Cancer-Fighting Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Benzinga
Study Results: Fennec Pharmaceuticals announced positive topline results from the Phase 2/3 STS-J01 trial of Pedmark, showing reduced rates of cisplatin-induced ototoxicity in pediatric patients, with only 24% and 16% experiencing hearing loss compared to higher rates in previous trials.
Safety and Efficacy: The study confirmed that Pedmark does not interfere with the antitumor activity of cisplatin, maintaining a high tumor response rate of approximately 95%, and was well-tolerated with no adverse events attributed to the drug.
Future Plans: Fennec intends to pursue regulatory registration for Pedmark in Japan and explore potential partnerships or licensing opportunities, with full study results to be presented in a scientific forum and submitted for publication.
Market Reaction: Following the announcement, Fennec Pharmaceuticals' stock experienced a slight decline of 0.78%, trading at $7.85.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on FENC
Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 14.67 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.460
Low
13.00
Averages
14.67
High
18.00
Current: 7.460
Low
13.00
Averages
14.67
High
18.00
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the outstanding shares.
- Market Strategy: This sale indicates a strategic adjustment in Southpoint's investment portfolio, as it still controls 2.7 million shares, but the reduced stake may reflect a cautious outlook on market conditions.
- Compliance Disclosure: The press release serves to comply with securities regulations, ensuring transparency and maintaining market trust, highlighting Southpoint's commitment to regulatory adherence.
- Future Outlook: Depending on market and other conditions, Southpoint may further adjust its ownership of Fennec through market transactions or other means, indicating flexibility in its investment strategy.
Continue Reading
Southpoint Disposes 1M Shares of Fennec Pharmaceuticals, Now Holds 8% Stake
- Share Disposition: On December 24, 2025, Southpoint Capital Advisors disposed of 1 million common shares of Fennec Pharmaceuticals at $7.50 per share, reducing its ownership stake to approximately 8% of the total outstanding shares.
- Market Strategy: The shares sold represent about 2.93% of Fennec's total outstanding shares, indicating Southpoint's flexible investment strategy in response to changing market conditions, which could impact Fennec's stock performance.
- Ownership Adjustment: Following this transaction, Southpoint retains control over 2.7 million shares of Fennec, reflecting ongoing interest in the company, although the reduction may suggest a response to short-term market volatility.
- Future Outlook: Southpoint indicated that it may further adjust its ownership of Fennec based on market and other conditions, demonstrating its proactive and flexible approach to investment management.
Continue Reading